Lenacapavir Dosage

Medically reviewed by Drugs.com. Last updated on Feb 14, 2023.

Usual Adult Dose for HIV Infection

Option 1:
Initial dose:

• Day 1: 927 mg subcutaneously, 600 mg orally
• Day 2: 600 mg orally

Maintenance dose:

• Every 6 months (+/- 2 weeks): 927 mg subcutaneously

Option 2:
Initial dose:

• Day 1: 600 mg orally
• Day 2: 600 mg orally
• Day 8: 300 mg orally
• Day 15: 927 mg subcutaneously

Maintenance dose:

• Every 6 months (+/- 2 weeks): 927 mg subcutaneously

Use: Treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults having multidrug resistant HIV-1 infection unresponsive to current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Renal Dose Adjustments

No adjustment recommended
End State Renal Disease (CrCl less than 15 mL/min): Data not available

Liver Dose Adjustments

Mild to moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Data not available

Dose Adjustments

Data not available

Precautions

CONTRAINDICATION:

• This drug should not be given with strong CYP3A inducers

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice (Subcutaneous injection):

• The subcutaneous injection of this drug is administered into the abdomen by a healthcare provider.
• Two 1.5 mL injections are required for a complete dose.
• The injection is single use only.
• In the event of a missed dose during the maintenance period, if more than 28 weeks have passed since last injection, the dosing should be re-initiated from Day 1 using either option 1 or 2 of the dosing regimen.

Storage requirements:

• Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
• Store in original blister pack or carton.
• Injection vial should be protected from light.

Reconstitution/preparation techniques:

• Injection preparation should be done aseptically.
• The solution in the vial should be inspected visually for particulate matter and discoloration.
• Once withdrawn, solution should be injected as soon as possible.
• Refer to manufacturer product information for additional instructions.

Patient advice:

• Advise patients to read the FDA-approved patient labeling.
• Patients should inform their healthcare provider about any concomitant prescription/non-prescription/herbal drugs.
• Patients should be informed that this drug may remain in the body and affect certain other drugs for up to 9 months after receiving their last injection.
• Patients should contact their healthcare provider if they develop any symptoms of infection after starting this treatment as signs and symptoms of inflammation from previous infections may occur.
• Patients should be counseled about the importance of medication adherence and regular scheduled visits in order to maintain viral suppression, to reduce risk of virologic response and development of resistance.
• In the event of missed dose or discontinuation of this drug or any antiretroviral combination of this treatment, patients should contact their healthcare provider immediately.
• Patients should be informed about the occurrence of injection site reactions (ISRs) such as swelling, pain, erythema, nodule, induration, pruritus, extravasation or mass, following administration of this drug.
• ISRs such as nodules and induration may take longer to resolve, and patients should reach out to their healthcare provider if these reactions persist.
• Pregnant women may register with an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant individuals exposed to this drug by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.
• HIV-1 positive lactating women should not breastfeed as the infection can be transmitted to the baby via breast milk.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer